FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Vasavada Amit		 2. Issuer Name and Ticker or Trading Symbol

MARRONE BIO INNOVATIONS INC [ MBII ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP & CTO
(Last)          (First)          (Middle)

C/O MARRONE BIO INNOVATIONS, INC., 7780-420 BRIER CREEK PARKWAY		 3. Date of Earliest Transaction (MM/DD/YYYY)

2/7/2022
(Street)

RALEIGH, NC 27617-7882
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

2/9/2022 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 2/7/2022  A  79481 (1)A$0.6321 118830 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $0.6321 2/7/2022  A   185455    3/7/2022 (2)2/7/2032 (3)Common Stock 185455 $0.00 185455 D  
Explanation of Responses:
(1) On February 7, the reporting person was granted 79,481 restricted stock units, which represent a contingent right to receive one share of Issuer's common stock. The restricted stock units vest pursuant to the Vesting Schedule (as defined in footnote (2)) and are delivered to the reporting person upon vesting.
(2) The awards vest in equal monthly installments over three years, subject to the recipient's continued employment by the Issuer through the applicable vesting date, provided that, in lieu of the terms of any change in control agreement in place between the Issuer and the reporting person, in the event that the reporting person resigns for Good Reason (as defined in the recipient's change in control agreement) or is terminated without Cause (as defined in recipient's change in control agreement) within twelve months of a Change in Control (as defined in recipient's change in control agreement), 50% of the unvested portion of the awards will become immediately vested (the "Vesting Schedule").
(3) The original Form 4, filed on February 9, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misstated the expiration date as February 6, 2025.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Vasavada Amit
C/O MARRONE BIO INNOVATIONS, INC.
7780-420 BRIER CREEK PARKWAY
RALEIGH, NC 27617-7882

SVP & CTO
Signatures
/s/ Linda V. Moore, as attorney in fact3/18/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Marrone Bio Innovations (NASDAQ:MBII)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Marrone Bio Innovations.
Marrone Bio Innovations (NASDAQ:MBII)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Marrone Bio Innovations.